Compare CVLT & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVLT | ACAD |
|---|---|---|
| Founded | 1996 | 1993 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.1B | 3.8B |
| IPO Year | 2006 | 2000 |
| Metric | CVLT | ACAD |
|---|---|---|
| Price | $103.78 | $22.22 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 18 | 22 |
| Target Price | ★ $139.53 | $30.55 |
| AVG Volume (30 Days) | 811.4K | ★ 1.6M |
| Earning Date | 04-28-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 69.12 |
| EPS | ★ 1.58 | 0.02 |
| Revenue | ★ $1,183,690,000.00 | $726,437,000.00 |
| Revenue This Year | $13.29 | $18.80 |
| Revenue Next Year | $13.20 | $11.70 |
| P/E Ratio | ★ $84.85 | $1,116.75 |
| Revenue Growth | 18.89 | ★ 40.45 |
| 52 Week Low | $71.75 | $19.69 |
| 52 Week High | $200.68 | $28.35 |
| Indicator | CVLT | ACAD |
|---|---|---|
| Relative Strength Index (RSI) | 63.25 | 51.96 |
| Support Level | $80.85 | $21.04 |
| Resistance Level | $129.23 | $22.91 |
| Average True Range (ATR) | 4.03 | 0.73 |
| MACD | 0.55 | 0.03 |
| Stochastic Oscillator | 86.17 | 57.89 |
CommVault Systems Inc provides data and information management software applications and services. The firm sells software licenses and services to large global enterprises, small- and midsize businesses, and government agencies through both its salesforce and its network of reseller partners. Its software solutions include Cleanroom Recovery, HyperScale X, Air Gap Protect, Compliance, Cloud Rewind, and Clumio Backtrack. The company operates in the United States and exports to many other countries.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on turning scientific promise to makes a difference for underserved neurological and rare disease communities around the world. It has two core franchises in neurological and rare diseases. Its neurological disease is anchored by the commercial product NUPLAZID (pimavanserin), which is the first and only drug approved by the U.S. (FDA) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis (PDP). Its rare disease is anchored by the commercial product DAYBUE, which is the first and only drug approved for the treatment of Rett syndrome. Its clinical-stage development efforts are focused on Alzheimer's disease psychosis, Lewy Body Dementia psychosis, and multiple other programs.